rs377022708 — ACAD9 Arg532Trp (R532W)

Pathogenic missense variant in the ACAD9 complex I assembly factor causing severe mitochondrial energy failure; the original riboflavin-responsive ACAD9 allele first identified by Gerards et al. 2011, producing hypertrophic cardiomyopathy, exercise intolerance, and lactic acidosis in homozygous or compound heterozygous carriers.

See your personal result for ACAD9

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ACAD9 R532W — Riboflavin-Responsive Mitochondrial Complex I Failure

Inside every cell, the mitochondrial electron transport chain converts the chemical energy of nutrients into ATP — the universal cellular fuel. Complex I11 Complex I
NADH:ubiquinone oxidoreductase, the largest of the five respiratory chain complexes, built from 44 protein subunits and assembled in a strictly ordered sequence is the entry point for electrons from NADH. Without functional complex I, tissues with the highest energy demands — heart muscle, skeletal muscle, and brain — fail first. ACAD9 is not itself a component of complex I, but it is one of the critical assembly factors required to build it: the protein physically interacts with NDUFAF1 and ECSIT to scaffold the assembly of complex I's proximal module, and its absence leaves the entire complex unassembled.

The R532W variant — a single cytosine-to-thymine substitution at nucleotide position 1,594 of the ACAD9 coding sequence — replaces the highly conserved arginine at protein position 532 with a bulky tryptophan residue. Protein structural modelling22 Protein structural modelling
Gerards M et al. Riboflavin-responsive oxidative phosphorylation complex I deficiency caused by defective ACAD9: new function for an old gene. Brain, 2011 shows that this substitution disrupts a stabilizing hydrogen bond within an α-helix of the ACAD9 protein, impairing the protein's ability to participate in complex I scaffolding. In the original family identified by Gerards et al., two siblings carried R532W in the homozygous state; a second unrelated patient carried R532W alongside a different ACAD9 mutation (compound heterozygous), confirming the allele is pathogenic in both configurations.

The Mechanism

ACAD9 belongs to the acyl-CoA dehydrogenase family and retains weak fatty acid oxidation enzymatic activity toward long-chain substrates, but its disease-causing role is firmly established as a complex I assembly factor. Nouws et al.33 Nouws et al.
Nouws J et al. Acyl-CoA dehydrogenase 9 is required for the biogenesis of oxidative phosphorylation complex I. Cell Metab, 2010 demonstrated that ACAD9 depletion by RNAi abolished complex I activity while leaving other respiratory chain complexes intact. ACAD9 assembles into an early intermediate complex during complex I biogenesis and is not a subunit of the final assembled complex — it acts transiently during construction, then is released.

The R532W substitution destabilizes the ACAD9 protein's tertiary structure, reducing both its FAD cofactor binding and its capacity to associate with NDUFAF1. Schiff et al.44 Schiff et al.
Schiff M et al. Complex I assembly function and fatty acid oxidation enzyme activity of ACAD9 both contribute to disease severity in ACAD9 deficiency. Hum Mol Genet, 2015 showed that both the assembly and the oxidation activities of ACAD9 contribute to disease severity, with the assembly function being the dominant determinant of phenotype. Importantly, ACAD9 requires FAD (derived from riboflavin, vitamin B2) as a cofactor — and this FAD dependence provides the mechanistic basis for riboflavin responsiveness: supplementing with high-dose riboflavin increases intracellular FAD, partially stabilizing the mutant ACAD9 protein and rescuing complex I assembly capacity.

The Evidence

The riboflavin responsiveness of ACAD9 deficiency is the most clinically actionable finding in this disorder. Gerards et al. 201155 Gerards et al. 2011
Gerards M et al. Brain, 2011 first demonstrated that high-dose riboflavin supplementation improved both complex I enzyme activity and clinical symptoms (exercise intolerance, lactic acidosis) in ACAD9-deficient patients. The largest subsequent cohort study, Repp et al. 201866 Repp et al. 2018
Repp BM et al. Clinical, biochemical and genetic spectrum of 70 patients with ACAD9 deficiency: is riboflavin supplementation effective? Orphanet J Rare Dis, 2018, recruited 70 ACAD9-deficient patients from European metabolic centers and found:

  • Complex I activity improved in 9 of 15 patient-derived fibroblast lines (60%) following riboflavin supplementation in vitro
  • Physicians reported a beneficial clinical effect in 20 of 31 treated patients (65%) for whom treatment data were available
  • In patients with disease onset before age 1, riboflavin treatment was associated with statistically significant better survival (p = 5.34 × 10⁻⁵)

The same cohort documented the cardinal clinical features: cardiomyopathy in 85% (44/56 patients), muscular weakness in 75%, exercise intolerance in 72%, and elevated lactate as a near-universal biochemical marker. Severe intellectual disability was rare (1 patient), and over 70% of surviving patients maintained normal activities of daily living — underscoring that riboflavin response, when present, can dramatically improve prognosis.

An ACAD9 cardiac-specific knockout mouse model Sinsheimer et al. 202177 Sinsheimer et al. 2021
Sinsheimer A et al. Development and characterization of a mouse model for Acad9 deficiency. Mol Genet Metab, 2021 confirmed the primacy of complex I failure: knockout hearts lacked all supercomplexes and isolated complex I activity, with only complex II retained, reproducing the fatal neonatal cardiomyopathy seen in the most severely affected human patients.

Practical Actions

For individuals carrying two copies of the R532W allele (homozygous) or one copy paired with another ACAD9 pathogenic variant (compound heterozygous), the critical intervention is establishing care with a metabolic specialist and initiating high-dose riboflavin supplementation if not already underway. Cardiac monitoring is essential given the 85% prevalence of cardiomyopathy. Exercise-induced symptoms (muscle pain, weakness, dyspnea) should prompt immediate medical evaluation; lactic acid levels are a useful biomarker for disease monitoring and treatment response.

For heterozygous carriers, no symptoms are expected — ACAD9 deficiency is autosomal recessive and one functional copy is sufficient. The significance of carrier status is primarily reproductive.

Interactions

ACAD9 deficiency caused by R532W requires compound heterozygosity (R532W paired with a second pathogenic ACAD9 allele on the other chromosome) or homozygosity. The most commonly reported second alleles in the literature include R127Q (c.380G>A) and R469W (c.1405C>T), both identified in the original Gerards 2011 cohort. The Repp 2018 cohort identified 34 known and 18 novel variants — no biallelic loss-of-function (two null alleles) was identified in any patient, suggesting complete ACAD9 loss is incompatible with survival. The presence and nature of the second allele influences both phenotype severity and riboflavin responsiveness. Compound heterozygotes should have both alleles identified to guide prognosis.

Nutrient Interactions

riboflavin increased_need

Genotype Interpretations

What each possible genotype means for this variant.

CC Non-Carrier Normal

Normal ACAD9 function — no complex I assembly impairment

With two reference C alleles, your ACAD9 protein is intact at the Arg532 position. This arginine residue contributes a stabilizing hydrogen bond in an α-helical domain important for ACAD9's interaction with the complex I assembly factors NDUFAF1 and ECSIT. Normal ACAD9 supports the biogenesis of all 44 subunits of mitochondrial respiratory chain complex I, enabling efficient NADH-driven electron transport and ATP production in mitochondria. No management is required based on this variant.

TT Homozygous Affected Deficient

Homozygous R532W — ACAD9 deficiency with complex I failure; high-dose riboflavin required

With two copies of the R532W allele, both copies of your ACAD9 protein carry the destabilizing Trp532 substitution. The mutant protein cannot efficiently interact with NDUFAF1 and ECSIT, the complex I assembly scaffold proteins, resulting in failure to assemble functional complex I. The clinical consequence is a severe energy deficit in tissues dependent on oxidative phosphorylation — particularly the heart (hypertrophic cardiomyopathy in 85% of ACAD9-deficient patients), skeletal muscle (exercise intolerance, weakness in 75%), and the metabolic system (lactic acidosis from anaerobic compensation).

Riboflavin responsiveness is the defining therapeutic opportunity. ACAD9 requires FAD (the active form of riboflavin, vitamin B2) as a cofactor for its function. High-dose riboflavin increases intracellular FAD availability, partially stabilizing the mutant Trp532 protein and partially restoring its capacity to scaffold complex I assembly. In the largest clinical cohort (Repp et al. 2018, 70 patients), 60% of patient-derived fibroblast lines showed improved complex I activity with riboflavin supplementation, 65% of treated patients had clinically beneficial responses, and early-onset patients who received riboflavin had statistically significantly better survival than untreated patients (p = 5.34 × 10⁻⁵).

The R532W allele was the first ACAD9 pathogenic variant described (Gerards et al. 2011, Brain) and identified riboflavin as a treatment. It is one of the most common single pathogenic ACAD9 alleles. The gene is named "ACAD9" (acyl-CoA dehydrogenase 9) because it structurally resembles fatty acid oxidation enzymes, but its primary disease-causing role is as a complex I assembly factor — this dual biology explains why classical newborn screening panels based on acylcarnitine profiles may not reliably detect ACAD9 deficiency.

CT Carrier Carrier

Heterozygous carrier — one R532W allele, complex I function preserved

Heterozygous carriers produce both functional (Arg532) and impaired (Trp532) ACAD9 protein from each allele respectively. The functional copy is sufficient to support normal complex I biogenesis — carrier individuals have not been reported to have any metabolic, cardiac, or neuromuscular symptoms on the basis of single-allele ACAD9 carrier status.

The clinical significance of carrier status is exclusively reproductive. If both parents are carriers of pathogenic ACAD9 variants (whether R532W or other pathogenic alleles), each pregnancy has a 25% probability of producing a child who inherits pathogenic alleles from both parents, resulting in ACAD9 deficiency. The condition typically presents in infancy or early childhood with hypertrophic cardiomyopathy and metabolic features including exercise intolerance and lactic acidosis. Riboflavin treatment is available and beneficial in the majority of affected individuals.